Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

N/ACompletedNCT04519944

Daiichi Sankyo666 enrolled

Overview

This study is designed to gain real-world clinical data on the peri- and post-procedural usage of anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation (NVAF) undergoing successful percutaneous coronary intervention (PCI) treated with edoxaban.

The study will assess real-world evidence data of anticoagulation and antiplatelet therapy in patients with NVAF undergoing PCI treated with edoxaban. The observation period will start 4 to 72 hours after removal of the guiding catheter of successful PCI in a hospital and ends 1 year after procedure. Follow-up telephone calls will take place approximately 1 month and 1 year after PCI. Real-world data of effectiveness of edoxaban and antiplatelet therapy, clinical events of interests, safety and quality of life (QoL) data of edoxaban will be collected.

Study Type

OBSERVATIONAL

Enrollment

666

Conditions

Non-valvular Atrial Fibrillation

Interventions

EdoxabanDRUG

This is an observational, prospective study; no treatment will be administered.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥ 18 years of age * Providing written informed consent (ICF) for participation in the study * NVAF treated with edoxaban * Successful PCI * No planned elective cardiac intervention for the whole duration of the study (up to 1 year) * Capability of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year) * Availability of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year) * Willingness of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year) * Not simultaneously participating in any interventional study * Life expectancy \> 1 year Exclusion Criteria: * Not applicable

Locations (66)

Outcomes

Primary Outcomes

Usage of Peri- and Post-procedural Anticoagulation and Antiplatelet Therapy in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention